Indications For and Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial
Author:
Publisher
Oxford University Press (OUP)
Subject
Epidemiology
Link
http://academic.oup.com/aje/article-pdf/176/2/156/264944/kwr524.pdf
Reference23 articles.
1. The natural history of benign prostatic hyperplasia: what have we learned in the last decade?
2. Risk behaviours and benign prostatic hyperplasia
3. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence
4. Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?
5. The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update;Expert Opinion on Emerging Drugs;2024-06-14
2. Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia;International Journal of Biological Sciences;2023
3. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease;Nature Communications;2022-04-19
4. Benefits of liposomal nonsteroid-anti-inflammatory drugs;Hospital Pharmacology - International Multidisciplinary Journal;2022
5. TNF Blockade Reduces Prostatic Hyperplasia and Inflammation while Limiting BPH Diagnosis in Patients with Autoimmune Disease;2021-03-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3